CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

Deutsche Bank upgraded Novartis (NVS) to Buy from Hold with a price target of CHF 110, up from CHF 100. The firm says the company’s ...

One of the most important launches for Novartis in recent years is off with a bang. Following a broad FDA approval for the adjuvant treatment of HR-positive, HER2-negative early breast cancer in ...

Novartis NOVN1.90%increase; green up pointing triangle forecasts further profit and sales growth this year after beating analysts’ expectations in the fourth quarter of 2024, despite looming ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

Empowering All Women to Own Their Breast Health "Novartis has been raising the bar in breast cancer care for the past 30+ years, most recently advancing a new treatment option for the broadest ...

But Steinfeld is gearing up for another arena. Steinfeld is teaming up with pharmaceutical company Novartis to raise awareness about breast cancer with a bold and empowering commercial that will ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that could reach up to $1 billion in biobucks. The San Diego-based biotech ...